Results 1 to 10 of about 20,120 (116)
Recent advances of oncolytic virus in cancer therapy
Oncolytic viruses have been taking the front stage in biological therapy for cancer recently. The first and most potent virus to be used in oncolytic virotherapy is human adenovirus.
Moumita Mondal +3 more
doaj +2 more sources
Recent progress in combination therapy of oncolytic vaccinia virus
In recent years, oncolytic viruses have emerged as promising agents for treating various cancers. An oncolytic virus is a non-pathogenic virus that, due to genetic manipulation, tends to replicate in and cause lysis of cancerous cells while leaving ...
Seyedeh Nasim Mirbahari +12 more
doaj +3 more sources
Chinese expert consensus on clinical application of recombinant oncolytic adenovirus in the treatment of malignant tumors [PDF]
Treatment using oncolytic virus as a new tumor immunologic agent has made continuous breakthroughs in basic and clinical research of tumor in recent years, and it is expected to play an important role in cancer immunotherapy in the future.
Expert Committee on Immunotherapy of Chinese Society of Clinical Oncology , Professional Committee on Cancer Biotherapy of Shanghai Anticancer Association
doaj +3 more sources
Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry
Rat H-1 parvovirus (H-1PV) is in clinical development for oncolytic therapy. Here, Kulkarni et al. identify LAMC1 as a modulator of H-1PV cell attachment and entry and find that LAMC1 levels and H-1PV oncolytic activity correlate in 59 tested cancer cell
Amit Kulkarni +18 more
doaj +1 more source
Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells
Clinical studies in glioblastoma and pancreatic carcinoma patients strongly support the further development of H-1 protoparvovirus (H-1PV)-based anticancer therapies. The identification of cellular factors involved in the H-1PV life cycle may provide the
Tiago Ferreira +9 more
doaj +1 more source
The XVIII International Parvovirus Workshop Rimini, Italy, 14–17 June 2022
The XVIII International Parvovirus Workshop took place in Rimini, Italy, from 14 to 17 June 2022 as an on-site event, continuing the series of meetings started in 1985 and continuously held every two years.
Giorgio Gallinella, Antonio Marchini
doaj +1 more source
Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis
H-1 protoparvovirus (H-1PV) is a self-propagating virus that is non-pathogenic in humans and has oncolytic and oncosuppressive activities. H-1PV is the first member of the Parvoviridae family to undergo clinical testing as an anticancer agent.
Tiago Ferreira +5 more
doaj +1 more source
The oncolytic effect of virotherapy derives from the intrinsic capability of the applied virus in selectively infecting and killing tumor cells. Although oncolytic viruses of various constructions have been shown to efficiently infect and kill tumor ...
Divya Ravirala +3 more
doaj +1 more source
Recent advances in oncolytic virus therapy for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a highly refractory cancer and the fourth leading cause of cancer-related mortality worldwide. Despite the development of a detailed treatment strategy for HCC, the survival rate remains unsatisfactory.
Licheng Zhu +14 more
doaj +1 more source
Application progress of oncolytic virus combined with immunotherapy in the treatment of malignant tumors [PDF]
The oncolytic virus (OV) therapy utilizes natural or genetically modified viruses to specifically target and infect tumor cells, leading to the destruction of cancer cells by the replication of the virus itself.
LIANG Yingyun, CHEN Jianhua
doaj +3 more sources

